These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29421995)

  • 1. New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension.
    Mercurio V; Bianco A; Campi G; Cuomo A; Diab N; Mancini A; Parrella P; Petretta M; Hassoun PM; Bonaduce D
    Curr Med Chem; 2019; 26(16):2844-2864. PubMed ID: 29421995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    Yao A
    J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macitentan for the treatment of pulmonary arterial hypertension.
    Sood N
    Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on pulmonary arterial hypertension pharmacotherapy.
    Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
    Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.
    Zheng W; Wang Z; Jiang X; Zhao Q; Shen J
    J Med Chem; 2020 Dec; 63(24):15153-15186. PubMed ID: 33314936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
    Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways in pulmonary arterial hypertension: the future is here.
    Sitbon O; Morrell N
    Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.
    Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
    J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in targeted therapy for pulmonary arterial hypertension in children.
    Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
    Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
    Belge C; Delcroix M
    Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for treatment of pulmonary arterial hypertension.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy in pulmonary arterial hypertension.
    Pugh ME; Hemnes AR; Robbins IM
    Clin Chest Med; 2013 Dec; 34(4):841-55. PubMed ID: 24267308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on pharmacotherapy for pulmonary hypertension.
    Prior DL; Adams H; Williams TJ
    Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.